Minocycline is effective and cosmetically preferred to clofazimine by leprosy patients in New York.
Levis
William R
WR
Spencer
Trudy I
TI
Ladizinski
Barry
B
D002991:Clofazimine / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use*; D003622:Dapsone / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced; D007917:Leprostatic Agents / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy*; D008911:Minocycline / Q000009:adverse effects / Q000627:therapeutic use*; D009518:New York; D057240:Patient Preference / Q000706:statistics & numerical data; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use
D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D008911:Minocycline; D012293:Rifampin